Larimar Therapeutics, Inc.

DB:ZA71 Stock Report

Market Cap: €107.4m

Larimar Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Carole Ben-Maimon

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage23.89%
CEO tenure5yrs
CEO ownership0.3%
Management average tenure4.8yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Carole Ben-Maimon's remuneration changed compared to Larimar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$95m

Dec 31 2024US$3mUS$600k

-US$81m

Sep 30 2024n/an/a

-US$65m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$3mUS$560k

-US$37m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$2mUS$528k

-US$35m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$2mUS$510k

-US$51m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$5mUS$268k

-US$42m

Compensation vs Market: Carole's total compensation ($USD2.51M) is above average for companies of similar size in the German market ($USD494.74K).

Compensation vs Earnings: Carole's compensation has been consistent with company performance over the past year.

CEO

Carole Ben-Maimon (65 yo)

5yrs

Tenure

US$2,511,649

Compensation

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...

Leadership Team

NamePositionTenureCompensationOwnership
Carole Ben-Maimon
CEO, President & Director5yrsUS$2.51m0.28%
€ 303.3k
Michael Celano
Secretary & CFO5yrsUS$1.38m0.13%
€ 138.5k
Gopi Shankar
Chief Development Officer2.3yrsUS$1.17m0.017%
€ 17.8k
John Berman
Vice President of Finance & Administration1.8yrsno datano data
Jennifer Johansson
Vice President of Legal & Compliance8.4yrsno datano data
Russell Clayton
Chief Medical Officer1.8yrsno datano data
Francis Conway
VP & Controller4.8yrsno datano data

4.8yrs

Average Tenure

64yo

Average Age

Experienced Management: ZA71's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Carole Ben-Maimon
CEO, President & Director5yrsUS$2.51m0.28%
€ 303.3k
Jonathan Leff
Independent Director5yrsUS$150.49kno data
Jeffrey Sherman
Independent Director1.6yrsUS$141.74k0%
€ 0
Frank Thomas
Independent Director10.9yrsUS$157.99k0.0031%
€ 3.4k
Thomas Hamilton
Independent Director5yrsUS$149.24k0.67%
€ 723.5k
Joseph Truitt
Independent Chairman of the Board5yrsUS$185.49k0.0043%
€ 4.6k
Giovanni Manfredi
Member of Scientific Advisory Board4.6yrsno datano data
Mark Payne
Member of Scientific Advisory Board4.6yrsno datano data
Marni Falk
Member of Scientific Advisory Board4.6yrsno datano data
Jill Ostrem
Member of Scientific Advisory Board2.7yrsno datano data

4.8yrs

Average Tenure

57.5yo

Average Age

Experienced Board: ZA71's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 18:26
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Larimar Therapeutics, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Samantha Lynn SemenkowCitigroup Inc
Samantha Lynn SemenkowCitigroup Inc